Could secondary prevention of coronary heart disease be more effective?

V. I. Makolkin

doi:undefined

Could secondary prevention of coronary heart disease be more effective?

V. I. Makolkin

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Beta-adrenoblockers (BAB) in secondary prevention of coronary heart disease (CHD) are not always effective, due to non-achieved target heart rate (HR). The reasons for that could include medication intolerance, baseline bradycardia (HR<55 bpm), II-III Stage atrio-ventricular blocks, and acute episodes of generalized weakness when HR is reduced. In these situations, BAB could be effectively combined with ivabradine (10-15 mg/d). This combination provides an opportunity to achieve target HR levels (60-55 bpm).

Keywords

сoronary heart disease, secondary prevention, beta-adrenoblockers, ivabradine

References

1. Pepine C.J., Abrams J., Marks R.G., et al. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994; 74:226-31.

2. Oganov R.G., Lepakhin V.K., Fitilev S.B. i dr. Osobennosti diagnostiki i terapii stabil'noi stenokardii v Rossiiskoi Federatsii (mezhdunarodnoe issledovanie ATP -Angina Treatment Pattern). Kardiologiya 2003; 5: 9-15.

3. Aronov D.M., Lupanov V.P. Vtorichnaya profilaktika khronicheskoi ishemicheskoi bolezni serdtsa. Lech vrach 2004; 7: 66-70.

4. Kokurina E.V., Shal'nova S.A., Kalinina A.M., Bochkareva E.V. Vtorichnaya profilaktika ishemicheskoi bolezni serdtsa: sovremennyi vzglyad na problemu. Kardiovask ter profil 2004; 6(2): 81-6.

5. Guidlines on management of stable angina pectoris -executive summary: The Task Force on the Management of stable angina pectoris of the European Society of cardiology. Eur Heart J 2006; 27: 1341-81.

6. Diagnostika i lechenie stabil'noi stenokardii. Rossiiskie rekomendatsii (vtoroi peresmotr). Kardiovask ter profil 2008; 6: Prilozhenie 4.

7. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. Pablished online September 1,2003, 1-7.

8. Oganov R.G., Lepakhin V.K., Fitilev S.B. i dr. Osobennosti diagnostiki i terapii stabil'noi stenokardii v Rossiiskoi Federatsii (mezhdunarodnoe issledovanie ATP -Angina Treatment Pattern). Kardiologiya 2003; 5: 9-15.

9. Lupanov V.P., Ageev F.T. Strategiya vedeniya i lecheniya bol'nykh stabil'noi ishemicheskoi bolezn'yu serdtsa v statsionare i ambulatornykh usloviyakh. Serdtse 2004; 3(2): 56-66.

10. Perepech N.B., Mikhailova I.E. Sovremennye R-adrenoblokatory: diapazon svoistv i obosnovanie predpochtenii. Serdtse 2004; 3: 130-6.

11. Oganov R.G., Kokurina E.V. Beta-blokatory pri khronicheskoi stabil'noi ishemicheskoi bolezni serdtsa. Ter arkhiv 2007; 3: 92-6.

12. Karpov Yu.A., Shubina A.T. Beta-blokatory v lechenii i profilaktiki ishemicheskoi bolezni serdtsa. Serdtse 2005; 1:32-5.

13. Gottlieb S., McCarter R., Vogel R. et al. Effect of beta-blocade on mortality among bigs risk patients after myocardial infarction. N Eng J Med 1998; 338: 489-97.

14. Von Armin. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. JACC 1996; 28: 20-4.

15. Shal'nova C.A., Deev A.D., Oganov R.G. Chastota pul'sa i smertnost' ot serdechno-sosudistykh zabolevanii u rossiiskikh muzhchin i zhenshchin. // Kardiologiya. 2005. № 10. S. 45.

16. Martsevich S.Yu., Kutishenko N.P. Vozmozhno li vosproizvesti dostizheniya dokazatel'noi meditsiny v real'noi klinicheskoi praktike? Kardiovask ter profil 2008; 3: 4-7.

17. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic disfunction (BEAUTIFUL): analysis of a randomized controlled trial. Lancet 2008; 372: 817-21.

18. Fox K., Ford I., Steg P.G., et al. Relationship between ivabradine treatment and cardiovascular jutcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337-45.

For citations:

Makolkin V.I. Could secondary prevention of coronary heart disease be more effective? Cardiovascular Therapy and Prevention. 2010;9(1):92-96. (In Russ.)

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

Cardiovascular Therapy and Prevention

Could secondary prevention of coronary heart disease be more effective?

Full Text:

Abstract

Keywords

About the Author

References

Review

For citations:

User

Cardiovascular Therapy and Prevention

Could secondary prevention of coronary heart disease be more effective?

Full Text:

Abstract

Keywords

About the Author

References

Review

For citations:

Cookies policy